

## 研究成果の刊行に関する一覧表

### 【書籍】

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
衛藤義勝 編集	ライソゾーム病 のすべて	衛藤義勝	別冊 医学のあゆみ	医歯薬出版	東京	2019年	1-151
衛藤義勝 編集	特集 ライソゾ ーム病—最新情 報と将来展望	衛藤義勝	日本臨床 特集	日本臨床社	東京	2019年	1-1384
衛藤義勝 (厚労省 研究班)	-	日本先天代 謝異常学会	ポンペ病診療 ガイドライン 2018	診断と治療 社	東京	2018年	1-80
衛藤義勝 (厚労省 研究班)	-	日本先天代 謝異常学会	ムコ多糖症 (MPS)Ⅱ型診 療ガイドライ ン2019	診断と治療 社	東京	2019年	1-40
衛藤義勝 (厚労省 研究班)	-	日本先天代 謝異常学会	副腎白質ジス トロフィー (ALD)診療ガ イドライン 2019	診断と治療 社	東京	2019年	1-64
衛藤義勝 (厚労省 研究班)	-	日本先天代 謝異常学会	シスチノーシ ス(シスチン蓄 積症)診療ガイ ドライン2019	診断と治療 社	東京	2019年	1-80

### 雑誌

### 論文

#### 1. 衛藤 義勝

1. Structural Determination of Lysosphingomyelin-509 and Discovery of Novel Class Lipids from Patients with Niemann-Pick Disease Type C. Maekawa M, Jinnoh I, Matsumoto Y, Narita A, Mashima R, Takahashi H, Iwahori A, Saigusa D, Fujii K, Abe A, Higaki K, Yamauchi S, Ozeki Y, Shimoda K, Tomioka Y, Okuyama T, **Eto Y**, Ohno K, T Clayton P, Yamaguchi H, Mano N. Int J Mol Sci. 2019 Oct 10;20(20).
2. Clinical findings of gadolinium-enhanced cardiac magnetic resonance in Fabry patients. Nojiri A, Anan I, Morimoto S, Kawai M, Sakuma T, Kobayashi M, Kobayashi H, Ida H, Ohashi T, **Eto Y**, Shibata T, Yoshimura M, Hongo K. J Cardiol. 2019 Oct 15. pii: S0914-5087(19)30292-8.
3. Development of a simultaneous analytical method for five conjugated cholesterol metabolites in urine and investigation of their performance as diagnostic markers for Niemann-Pick disease type C. Maekawa M, Jinnoh I, Narita A, Iida T, Saigusa D, Iwahori A, Nittono H, Okuyama T, **Eto Y**, Ohno K, Clayton PT, Yamaguchi H, Mano N. J Lipid Res. 2019 Oct 4.
4. Future clinical and biochemical predictions of Fabry disease in females by methylation studies of the GLA gene. Hossain MA, Wu C, Yanagisawa H, Miyajima T, Akiyama K, **Eto Y**. Mol Genet Metab Rep. 2019 Jul 24; 20: 100497.

5. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, Borgo A, Braunlin E, **Eto Y**, Gold JI, Jester A, Jones SA, Karsli C, Mackenzie W, Marinho DR, McFadyen A, McGill J, Mitchell JJ, Muenzer J, Okuyama T, Orchard PJ, Stevens B, Thomas S, Walker R, Wynn R, Giugliani R, Harmatz P, Hendriksz C, Scarpa M; MPS Consensus Programme Steering Committee; MPS Consensus Programme Co-Chairs. *Orphanet J Rare Dis.* 2019 Jun 13;14(1):137. doi: 10.1186/s13023-019-1074-9.
6. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance. Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, Borgo A, Braunlin E, **Eto Y**, Gold JI, Jester A, Jones SA, Karsli C, Mackenzie W, Marinho DR, McFadyen A, McGill J, Mitchell JJ, Muenzer J, Okuyama T, Orchard PJ, Stevens B, Thomas S, Walker R, Wynn R, Giugliani R, Harmatz P, Hendriksz C, Scarpa M; MPS Consensus Programme Steering Committee; MPS Consensus Programme Co-Chairs. *Orphanet J Rare Dis.* 2019 May 29;14(1):118. doi: 10.1186/s13023-019-1080-y.
7. Diagnostic performance evaluation of sulfate-conjugated cholesterol metabolites as urinary biomarkers of Niemann-Pick disease type C. Maekawa M, Narita A, Jinnoh I, Iida T, Marquardt T, Mengel E, **Eto Y**, Clayton PT, Yamaguchi H, Mano N. *Clin Chim Acta.* 2019 Mar 12;494:58-63.
8. Dysregulated DNA methylation of GLA gene was associated with dysfunction of autophagy. Yanagisawa H, Hossain MA, Miyajima T, Nagao K, Miyashita T, **Eto Y**. *Mol Genet Metab.* 2019 Mar 7. pii: S1096-7192(19)30014-9.
9. A case of Niemann-Pick disease type C with neonatal liver failure initially diagnosed as neonatal hemochromatosis. Kumagai T, Terashima H, Uchida H, Fukuda A, Kasahara M, Kosuga M, Okuyama T, Tsunoda T, Inui A, Fujisawa T, Narita A, **Eto Y**, Kubota M. *Brain Dev.* 2019 Feb 5.
10. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial. Okuyama T, **Eto Y**, Sakai N, Minami K, Yamamoto T, Sonoda H, Yamaoka M, Tachibana K, Hirato T, Sato Y. *Mol Ther.* 2019 Feb 6;27(2):456-464.
11. Phenotypic variability of Niemann-Pick disease type C including a case with clinically pure schizophrenia: a case report. Kawazoe T, Yamamoto T, Narita A, Ohno K, Adachi K, Nanba E, Noguchi A, Takahashi T, Maekawa M, **Eto Y**, Ogawa M, Murata
12. A Case of Adult-onset Pompe Disease with Cerebral Stroke and Left Ventricular Hypertrophy. Hossain MA, Miyajima T, Akiyama K, **Eto Y**. *J Stroke Cerebrovasc Dis.* 2018 Nov;27(11):3046-3052.
13. The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients. Hongo K, Ito K, Date T, Anan I, Inoue Y, Morimoto S, Ogawa K, Kawai M, Kobayashi H, Kobayashi M, Ida H, Ohashi T, Taniguchi I, Yoshimura M, **Eto Y**. *Mol Genet Metab.* 2018 Jun;124(2):143-151.
14. P-Tau and Subunit c Mitochondrial ATP Synthase Accumulation in the Central Nervous System of a Woman with Hurler-Scheie Syndrome Treated with Enzyme Replacement Therapy for 12 Years. Kobayashi H, Ariga M, Sato Y, Fujiwara M, Fukasawa N, Fukuda T, Takahashi H, Ikegami M, Kosuga M, Okuyama T, **Eto Y**, Ida H. *JIMD Rep.* 2018; 41: 101-107.
15. Characteristics of PPT1 and TPP1 enzymes in neuronal ceroid lipofuscinosis (NCL) 1 and 2 by dried blood spots (DBS) and leukocytes and their application to newborn screening. Itagaki R, Endo M, Yanagisawa H, Hossain MA, Akiyama K, Yaginuma K, Miyajima T, Wu C, Iwamoto T, Igarashi J, Kobayashi Y, Tohyama J, Iwama K, Matsumoto N, Shintaku H, **Eto Y**. *Mol Genet Metab.* 2018 May;124(1):64-70

## 2. 酒井 規夫

- 1) Hughes DA ,Nicholls K ,Shankar SP ,Sunder-Plassmann G ,Koeller D ,Nedd K ,Vockley G ,Hamazaki T ,Lachmann R ,Ohashi T ,Olivotto I ,Sakai N ,Deegan P ,Dimmock D ,Eyskens F ,Germain DP ,Goker-Alpan O ,Hachulla E ,Jovanovic A ,Lourenco CM ,Narita I ,Thomas M ,Wilcox WR ,Bichet DG ,Schiffmann R ,Ludington E ,Viereck C ,Kirk J ,Yu J ,Johnson F ,Boudes P ,Benjamin ER ,Lockhart DJ ,Barlow C ,Skuban N ,Castelli JP ,Barth J Feldt-Rasmussen U., Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study., *J Med Genet.* 2017 Apr;54(4):288-296
- 2) Kondo H , Maksimova N , Otomo T , Kato H , Imai A , Asano Y , Kobayashi K , Nojima S , Nakaya A , Hamada Y , Irahara K , Gurinova E , Sukhomyasova A , Nogovicina A , Savvina M , Yoshimori T , Ozono K , Sakai N Mutation in VPS33A affects metabolism of glycosaminoglycans: a new type of mucopolysaccharidosis with severe systemic symptoms. *Hum Mol Genet.* 26(1):173-183, 2017
- 3) Nishiumi F ,Ogawa M ,Nakura Y ,Hamada Y ,Nakayama M ,Mitobe J ,Hiraide A ,Sakai N ,Takeuchi M , Yoshimori T , Yanagihara I Intracellular fate of *Ureaplasma parvum* entrapped by host cellular autophagy., *Microbiologyopen.* 2017 Jan 15. . doi: 10.1002/mbo3.441. [Epub ahead of print]
- 4) Yuan JH , Hashiguchi A , Yoshimura A , Sakai N , Takahashi MP , Ueda T , Taniguchi A , Okamoto S , Kanazawa N , Yamamoto Y , Saigoh K , Kusunoki S , Ando M , Hiramatsu Y , Okamoto Y , Takashima H., WNK1/HSN2 Founder Mutation in Patients with Hereditary Sensory and Autonomic Neuropathy: a Japanese cohort study., *Clin Genet.* 2017 Apr 19. doi: 10.1111/cge.13037. [Epub ahead of print]
- 5) Tajima G , Hara K , Tsumura M , Kagawa R , Okada S , Sakura N , Maruyama S , Noguchi A , Awaya T , Ishige M , Ishige N , Musha I , Ajihara S , Ohtake A , Naito E , Hamada Y , Kono T , Asada T , Sasai H , Fukao T , Fujiki R , Ohara O , Bo R , Yamada K , Kobayashi H , Hasegawa Y , Yamaguchi S , Takayanagi M , Hata I , Shigematsu Y , Kobayashi M., Newborn screening for carnitine palmitoyltransferase II deficiency using (C16+C18:1)/C2: Evaluation of additional indices for adequate sensitivity and lower false-positivity., *Mol Genet Metab.* 2017 Nov;122(3):67-75.
- 6) Kondo H , Fujita Y , Mizuno Y , Kihara M , Murayama K., Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes with severe systemic symptoms: Pathology and biochemistry., *Pediatr Int.* 2018 Mar;60(3):300-302.
- 7) Irahara-Miyana K , Otomo T , Kondo H , Hossain MA , Ozono K , Sakai N., Unfolded protein response is activated in Krabbe disease in a manner dependent on the mutation type., *J Hum Genet.* 2018 Apr 3. doi: 10.1038/s10038-018-0445-8.
- 8) Irahara-Miyana K , Enokizono T , Ozono K , Sakai N., Exonic deletions in GALC are frequent in Japanese globoid-cell leukodystrophy patients., *Hum Genome Var.* 2018 Oct 5;5:28. doi: 10.1038/s41439-018-0027-5
- 9) Okuyama T , Eto Y , Sakai N , Minami K , Yamamoto T , Sonoda H , Yamaoka M , Tachibana K , Hirato T , Sato Y., Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial., *Mol Ther.* 2019 Feb 6;27(2):456-464. doi: 10.1016/j.ymthe.2018.12.005. Epub 2018 Dec 8.
- 10) Miwa K , Yagita Y , Sakaguchi M , Kitagawa K , Sakai N , Mochizuki H., Effect of Enzyme Replacement Therapy on Basilar Artery Diameter in Male Patients With Fabry Disease., *Stroke.* 2019 Mar 11. doi: 10.1161 [Epub ahead of print]

- 11) Takeyari S, Takakuwa S, Miyata K, Yamamoto K, Nakayama H, Ohata Y, Fujiwara M, Kitaoka T, Kubota T, Namba N, Sakai N, Ozono K., Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report., *Clin Pediatr Endocrinol*. 2019;28(1):1-7. doi: 10.1297/cpe.28.1. Epub 2019 Jan 31.
- 12) Koh S, Haruna M, Asonuma S, Maeda N, Hamano T, Sakai N, Hara C, Maruyama K, Nishida K., Quantitative evaluation of visual function in patients with cornea verticillata associated with Fabry disease., *Acta Ophthalmol*. 2019 May 24.
- 13) Murata Y, Kurosaka H, Ohata Y, Aikawa T, Takahata S, Fujii K, Miyashita T, Morita C, Inubushi T, Kubota T, Sakai N, Ozono K, Kogo M, Yamashiro T., A novel PTCH1 mutation in basal cell nevus syndrome with rare craniofacial features., *Hum Genome Var*. 2019 Apr 2;6:16. doi: 10.1038/s41439-019-0047-9
- 14) Silventoinen K, Jelenkovic A, Yokoyama Y, Sund R, Sugawara M, Tanaka M, Matsumoto S, Bogl LH, Freitas DL, Maia JA, Hjelmborg JVB, Aaltonen S, Piirtola M, Latvala A, Calais-Ferreira L, Oliveira VC, Ferreira PH, Ji F, Ning F, Pang Z, Ordoñana JR, Sánchez-Romera JF, Colodro-Conde L, Burt SA, Klump KL, Martin NG, Medland SE, Montgomery GW, Kandler C, McAdams TA, Eley TC, Gregory AM, Saudino KJ, Dubois L, Boivin M, Brendgen M, Dionne G, Vitaro F, Tarnoki AD, Tarnoki DL, Haworth CMA, Plomin R, Öncel SY, Aliev F, Medda E, Nisticò L, Toccaceli V, Craig JM, Saffery R, Siribaddana SH, Hotopf M, Sumathipala A, Rijdsdijk F, Jeong HU, Spector T, Mangino M, Lachance G, Gatz M, Butler DA, Gao W, Yu C, Li L, Bayasgalan G, Narandalai D, Harden KP, Tucker-Drob EM, Christensen K, Skytthe A, Kyvik KO, Derom CA, Vlietinck RF, Loos RJF, Cozen W, Hwang AE, Mack TM, He M, Ding X, Silberg JL, Maes HH, Cutler TL, Hopper JL, Magnusson PKE, Pedersen NL, Dahl Aslan AK, Baker LA, Tuvblad C, Bjerregaard-Andersen M, Beck-Nielsen H, Sodemann M, Ullemar V, Almqvist C, Tan Q, Zhang D, Swan GE, Krasnow R, Jang KL, Knafo-Noam A, Mankuta D, Abramson L, Lichtenstein P, Krueger RF, McGue M, Pahlen S, Tynelius P, Rasmussen F, Duncan GE, Buchwald D, Corley RP, Huibregtse BM, Nelson TL, Whitfield KE, Franz CE, Kremen WS, Lyons MJ, Ooki S, Brandt I, Nilsen TS, Harris JR, Sung J, Park HA, Lee J, Lee SJ, Willemsen G, Bartels M, van Beijsterveldt CEM, Llewellyn CH, Fisher A, Rebato E, Busjahn A, Tomizawa R, Inui F, Watanabe M, Honda C, Sakai N, Hur YM, Sørensen TIA, Boomsma DI, Kaprio J., The CODATwins Project: The Current Status and Recent Findings of COllaborative Project of Development of Anthropometrical Measures in Twins., *Twin Res Hum Genet*. 2019 Jul 31:1-9. doi: 10.1017/thg.2019.35.
- 15) Yagita Y, Sakai N, Miwa K, Ohara N, Tanaka M, Sakaguchi M, Kitagawa K, Mochizuki H., Magnetic Resonance Imaging Findings Related to Stroke Risk in Japanese Patients With Fabry Disease., *Stroke*. 2019 Jul 24;STROKEAHA119025528. doi: 10.1161/STROKEAHA.119.025528
- 16) Shiraishi H, Yamada K, Oki E, Ishige M, Fukao T, Hamada Y, Sakai N, Ochi F, Watanabe A, Kawakami S, Kuzume K, Watanabe K, Sameshima K, Nakamagoe K, Tamaoka A, Asahina N, Yokoshiki S, Miyakoshi T, Oba K, Isoe T, Hayashi H, Yamaguchi S, Sato N., Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey., *Mol Genet Metab Rep*. 2019 Jul 25;20:100496. doi: 10.1016/j.ymgmr.2019.100496. eCollection 2019 Sep. PMID:3137234
- 17) Sakurai M, Azuma J, Hamada Y, Yamamoto T, Sakai N., Early juvenile Tay-Sachs disease with atypical symptoms., *Pediatr Int*. 2019 Jun;61(6):611-613. doi:10.1111/ped.13848

- 18) Ichiei Narita, Toya Ohashi, Norio Sakai, Takashi Hamazaki, Nina Skuban, Jeffrey P. Castelli, Hjalmar Lagast & Jay A. Barth, Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study, *Clinical and Experimental Nephrology* 24, 157– 166 (2020)
- 19) Honda C, Watanabe M, Tomizawa R; Osaka Twin Research Group, Sakai N., Update on Osaka University Twin Registry: An Overview of Multidisciplinary Research Resources and Biobank at Osaka University Center for Twin Research., *Twin Res Hum Genet.* 2019 Dec 27:1-5. doi: 10.1017/thg.2019.70. [Epub ahead of print]

3. 高橋 勉

Kawazoe T, Yamamoto T, Narita A, Ohno K, Adachi K, Nanba E, Noguchi A, Takahashi T, Maekawa M, Eto Y, Ogawa M, Murata M, Takahashi Y. Phenotypic variability of Niemann-Pick disease type C including a case with clinically pure schizophrenia: a case report. *MC Neurol.*, 2018, 18, 117.

Ota S, Noguchi A, Kondo D, Nakajima Y, Ito T, Arai H, Takahashi T. An early-onset neuronopathic form of acid sphingomyelinase deficiency: A *SMPD1* p.C133Y mutation in the saposin domain of acid sphingomyelinase.

*Tohoku J Exp Med.*, 2020, 250: 5-11.

4. 高柳 正樹

1. 高柳 正樹 . 先天代謝異常症におけるトランジションの現状と問題点 . 外来小児科 vol18:p304-308,2015.

2. 高柳 正樹. 【小児慢性疾患の成人期移行の現状と問題点】 先天性代謝異常 糖原病. 小児科臨床 vol69: p684-688, 2016.

5. 辻 省次

1. T Matsukawa, et al. Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy. *Brain Communications.* 2020;2:fcz048

6. 檜垣 克美

1. Front S, Biela-Banaś A, Burda P, Ballhausen D, Higaki K, Caciotti A, Morrone A, Charollais-Thoenig J, Gallienne E, Demotz S, Martin OR. (5aR)-5a-C-Pentyl-4-epi- isofagomine: A powerful inhibitor of lysosomal  $\beta$ -galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B. *Eur J Med Chem.* 2017; 126:160-170.
2. García-Moreno MI, de la Mata M, Sánchez-Fernández EM, Benito JM, Díaz-Quintana A, Fustero S, Nanba E, Higaki K, Sánchez-Alcázar JA, García Fernández JM, Ortiz Mellet C. Fluorinated Chaperone- $\beta$ -Cyclodextrin Formulations for  $\beta$ -Glucocerebrosidase Activity Enhancement in Neuronopathic Gaucher Disease. *J Med Chem.* 2017; 60(5):1829-1842.
3. Okada Y, Ueda E, Kondo Y, Ishitsuka Y, Irie T, Higashi T, Motoyama K, Arima H, Matuso M, Higaki K, Ohno K, Nishikawa J, Ichikawa A. Role of 6-O- $\alpha$ -maltosyl- $\beta$ - cyclodextrin in lysosomal cholesterol deprivation in *Npc1*-deficient Chinese hamster ovary cells. *Carbohydr Res.* 2018; 455:54-61.
4. Mena-Barragán T, García-Moreno MI, Sevsek A, Okazaki T, Nanba E, Higaki K, Martin MI, Pieters RJ, García Fernández JM, Ortiz Mellet C. Probing the inhibitor versus chaperone properties of sp2-iminosugars towards human b-glucocerebrosidase: a picomolar chaperone for Gaucher disease. *Molecules* 2018
5. Riquez-Cuadro R, Matsumoto R, Caballero FO, Nanba E, Higaki K, Garcia-Fernandez JM, Mellet CO, Multipoint enzyme inhibition in a medicinal chemistry context: pharmacological chaperones for the treatment of  $\alpha$ -Mannosidosis. *J Med Chem* 62, 5832-5843, 2019
6. Ikuno M, Yamakado H, Akiyama H, Parajuli LK, Taguchi K, Hara J, Uemura N, Hatanaka Y, Higaki K, Ohno K, Tanaka M, Koike M, Hirabayashi Y, Takahasi R, GBA haploinsufficiency accelerates alpha synuclein

pathology with altered lipid metabolism in a prodromal model of Parkinson's disease **Hum Mol Genet** 28, 1894-1904, 2019

7. Gonzalez-Cuesta M, Goyard D, Nanba E, Higaki K, Garcia-Fernandez JM, Renaudet O, Mellet CO, Multivalent glycolignads with lectin/enzyme dual specificity: self-deliverable glycosidase regulators. **ChemComm**, 55, 12845-12848, 2019

7. 鈴木 康之

- Khan SA, Suzuki Y, Tomatsu S, et al. Epidemiology of mucopolysaccharidoses. *Mol Genet Metab.* 2017 Jul;121(3):227-240.
- Stapleton M, Suzuki Y, Fukao T, Orii T, Ida H, Tomatsu S, et al. Critical review of current MPS guidelines and management. *Mol Genet Metab* 2018; <https://doi.org/10.1016/j.yimgme.2018.07.001>
- Orii KE, Tomatsu S, Suzuki Y, Fukao T, Matsumoto T, et al. Safety Study of Sodium Pentosan Polysulfate for Adult Patients with Mucopolysaccharidosis Type II. *Diagnostics* 2019;9:226 doi:10.3390/diagnostics9040226

8. 奥山 虎之

「ムコ多糖症 (MPS) I 型診療ガイドライン 2019」、監修：厚生労働省難治性疾患等政策研究事業ライソゾーム病 (ファブリー病含む) に関する調査研究班、編集：ムコ多糖症 (MPS) I 型診療ガイドライン作成委員会、2019 年 12 月、診断と治療社

9. 坪井 一哉

- 1) Katsuta H, Tsuboi K, Yamamoto H, Goto H. Correlations Between Serum Cholesterol and Vascular Lesions in Fabry Disease Patients. *Circ J.* 2018 Oct 3. doi: 10.1253/circj.CJ-18-0378.
- 2) Tsuboi K, Yamamoto H. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients. *BMC Pharmacol Toxicol.* 2017 Jun 7;18(1):43. doi: 10.1186/s40360-017-0152-7.
- 3) 坪井一哉. ファブリー病. *神経治療* 9: 288-292, 2018
- 4) 坪井一哉, 神崎保. ファブリー病の皮膚病変. *BRAIN and NERVE* 74(4): 354-359, 2019
- 5) 坪井一哉. *脳神経内科* 91(2): 233-240, 2019

10. 松田 純子

- 1) **松田純子**: スフィンゴ脂質活性化タンパク質 サポシン の生理機能と疾患 . 生化学 . 第 89 巻-6 号 , 808-819 (2017) .
- 2) Ono S, Matsuda J, Saito A, Yamamoto Y, Fujimoto W, Shimizu H, Dateki S, and Ouchi K.: A case of sitosterolemia due to compound heterozygous mutations in ABCG5: clinical features and treatment outcomes obtained with colestimide and ezetimibe. *Clin Pediatr Endocrinol.* 26 (1), 17-23 (2017).
- 3) Inamura N, Kito M, Go S, Kishi S, Hosokawa M, Asai K, Takakura N, Takebayashi H, Matsuda J, Enokido Y. Developmental defects and aberrant accumulation of endogenous psychosine in oligodendrocytes in a murine model of Krabbe disease. *Neurobiol Dis.* 120:51-62 (2018).
- 4) Ono S, Matsuda J, Watanabe E, et al. Novel neuroblastoma amplified sequence (NBAS) mutations in a Japanese boy with fever-triggered recurrent acute liver failure. *Hum Genome Var.*, 6:2 (2019).
- 5) Oji Y, Hatano T, Matsuda J (31/32), et al. Variants in saposin D domain of prosaposin gene linked to Parkinson's disease. *Brain.* (2020) Mar 23. pii: awaa064. doi: 10.1093/brain/awaa064. [Epub ahead of print]

## 11. 下澤 伸行

### 1. 英文著書 (ALD & ペルオキシソーム病関連)

Imanaka T, Shimozawa N (Eds.), Peroxisomes: Biogenesis, Function, and Role in Human Disease, Springer, 2020, pp1-279

### 2. 英文原著 (ALD & ペルオキシソーム病関連)

Yamashita T, Mitsui J, Shimozawa N, Takashima S, Umemura H, Sato K, Takemoto M, Hishikawa N, Ohta Y, Matsukawa T, Ishiura H, Yoshimura J, Doi K, Morishita S, Tsuji S, Abe K. Ataxic form of autosomal recessive PEX10-related peroxisome biogenesis disorders with a novel compound heterozygous gene mutation and characteristic clinical phenotype. *J Neurological Sciences* 2017; 375: 424-429. CS 1.98

Horikawa Y, Enya M, Yoshikura N, Kitagawa J, Takashima S, Shimozawa N, Takeda J. A first case of adrenomyelo- neuropathy with mutation Y174S of the adrenoleukodystrophy gene. *Neuro Endocrinol Lett* 2017; 38(1): 13-18.

Morita M, Honda A, Kobayashi A, Watanabe Y, Watanabe S, Kawaguchi K, Takashima S, Shimozawa N, Imanaka T. Effect of Lorenzo's Oil on Hepatic Gene Expression and the Serum Fatty Acid Level in abcd1-Deficient Mice. *JIMD Rep* 2017 May 31.

Tsuboi T, Tanaka Y, Yoshida Y, Nakamura T, Shimozawa N, Katsuno M. Highly asymmetric and subacutely progressive motor weakness with unilateral T2-weighted high intensities along the pyramidal tract in the brainstem in adrenomyeloneuropathy. *J Neurol Sci* 2017; 381: 107-109.

Hama K, Fujiwara Y, Morita M, Yamazaki F, Nakashima Y, Takei S, Takashima S, Setou M, Shimozawa N, Imanaka T, Yokoyama K. Profiling and Imaging of Phospholipids in Brains of Abcd1- Deficient Mice. *Lipids*. 2018; 53 (1) :85-102.

Morita M, Matsumoto S, Sato A, Inoue K, Kostsin DG, Yamazaki K, Kawaguchi K, Shimozawa N, Kemp S, Wanders RJ, Kojima H, Okabe T, Imanaka T. Stability of the ABCD1 Protein with a Missense Mutation: A Novel Approach to Finding Therapeutic Compounds for X-Linked Adrenoleuko- dystrophy. *JIMD Rep*. 2018 doi: 10.1007/8904\_2018\_118.

Kato K, Maemura R, Wakamatsu M et al. N.Allogeneic stem cell transplantation with reduced intensity conditioning for patients with adrenoleukodystrophy. *Mol Genet Metab Rep*. 2018 Nov 20;18:1-6.

Takashima S, Saitsu H, Shimozawa N. Expanding the concept of peroxisomal diseases and efficient diagnostic system in Japan. *J Hum Genet* 64, 145-152 (2019)

Zaabi NA, Kendi A, Al-Jasmi F, Takashima S, Shimozawa N, Al-Dirbashi OY: Atypical PEX16 peroxisome biogenesis disorder with mild biochemical disruptions and long survival. *Brain Dev* 41, 57-65 (2019)

Sakurai K, Ohashi T, Shimozawa N, Seo JH, Okuyama T, Ida H. Characteristics of Japanese patients with X-linked adrenoleukodystrophy and concerns of their families from the 1st registry system. *Brain Dev* 41: 50-56 (2019)

Matsuda Y, Morino H, Miyamoto R, Kurashige T, Kume K, Mizuno N, Kanaya Y, Tada Y, Ohsawa R, Yokota K, Shimozawa N, Maruyama H, Kawakami H. Biallelic mutation of HSD17B4 induces middle age-onset spinocerebellar ataxia. *Neurol Genet*. 16;6: e396 ( 2020 )

Tanaka H, Amano N, Tanaka K, Katsuki T, Adachi T, Shimozawa N, Kawai T. A 29-year-old patient with adrenoleukodystrophy presenting with Addison's disease. *Endocr J*. doi: 10.1507/endocrj.EJ19-0576 ( 2020 )

Hama K, Fujiwara Y, Takashima S, Hayashi Y, Yamashita A, Shimozawa N, Yokoyama K. Hexacosenoyl-CoA is the most abundant very long-chain acyl-CoA in ATP-binding cassette transporter D1-deficient cells. *J Lipid Res pii: jlr.P119000325 ( 2020 )*

### 3. 和文著書

下澤伸行 : 副腎白質ジストロフィー・ペルオキシソーム病と遺伝カウンセリング 遺伝子医学 MOOK 別冊 シリーズ 4 最新小児・周産期遺伝医学研究と遺伝カウンセリング pp195-200.メディカルドウ.大阪. 2019 年 11 月

日本先天代謝異常学会編：副腎白質ジストロフィー（ALD）診療ガイドライン 2019 p1-46.診断と治療社.  
東京.2019年11月

#### 4.和文総説

下澤伸行. 副腎白質ジストロフィー（ALD）新生児マススクリーニングの意義と課題：日本マススクリーニング学会誌 2017年；27(3)：239 - 242.

下澤伸行：ペルオキシソーム病（副腎白質ジストロフィーを除く）指定難病ペディア 2019 日本医師会雑誌 148 特別号(1) 286. 2019年6月

下澤伸行：副腎白質ジストロフィーマススクリーニング国内導入に向けての現状と課題と提案. 日本マススクリーニング学会誌 29(3) 245-248. 2019年12月

下澤伸行. ペルオキシソーム病: 別冊日本臨床. 新領域別症候群シリーズ 37 精神医学症候群(第2版)  
東京：日本臨床社；2017年：190 - 195.

#### 12. 今中 常雄

1. 日本先天代謝異常学会：副腎白質ジストロフィー（ALD）診療ガイドライン 2019
2. ムコ多糖症(MPS)I型診療ガイドライン作成委員会：ムコ多糖症(MPS)I型診療ガイドライン 2019
3. Imanaka, T., Shimozawa, N. eds.: Peroxisomes: Biogenesis, Function, and Role in Human Disease. Springer Nature 2020

#### 13. 小林 博司

副腎白質ジストロフィー（ALD）診療ガイドライン2019 日本先天代謝異常学会編集  
2019年11月1日第1版発行 診断と治療社

#### 14. 加我 牧子

- 1.日本先天代謝異常学会：副腎白質ジストロフィー（ALD）診療ガイドライン 2019
2. Kaga M.Neurophysiology and Neuropsychology in ALD. In Imanaka, T., Shimozawa, N. eds.: Peroxisomes: Biogenesis, Function, and Role in Human Disease. Springer Nature 2020
3. Kato K,et al. Allogeneic SCT with reduced intensity conditioning for patients with ALD. Molec. Gen. Metabol. Rep. 18:1-6, 2019

#### 15. 横山 和明

- 1) Comprehensive quantitation using two stable isotopically labeled species and direct observation of N-acyl moiety of sphingomyelin by LC-MS. K. Hama, K. Yokoyama et al. **Lipids**. (2017) 52, 789-799. PMID: 28770378
- 2) Profiling and imaging of phospholipids in brains of Abcd1-deficient mice. K. Hama, K. Yokoyama et al **Lipids**. (2018) 53, 85-102. PMID: 29469952
- 3) Quantitative and Qualitative Method for Sphingomyelin by LC-MS Using Two Stable Isotopically Labeled Sphingomyelin Species.(2018) Hama K, Yokoyama K. et al. **Journal of visualized experiment**\_May, doi: 10.3791/57293. PMID: 29782002
- 4) Lipidomics of Peroxisomal Disorders. Hama K., Yokoyama K. et al., Chapter 11 p249-260, in **Peroxisomes: Biogenesis, Function, and Role in Human Disease**, Springer (2019)
- 5) Hexacosenoyl-CoA is the most abundant very long-chain acyl-CoA in ATP-binding cassette transporter D1-deficient cells. Hama K., Yokoyama K. et al. **Journal of Lipid Research**. (2020) doi: 10.1194/jlr.P119000325, PMID: 32075856
- 6) Mass spectrometry in combination with a chiral column and multichannel-MRM allows comprehensive analysis of glycosphingolipid molecular species from mouse brain. Fujiwara Y., Yokoyama K. et al. **Carbohydrate Research**. (2020) doi: 10.1016/j.carres.2020.107959, PMID: 32120021

#### 16. 渡邊 順子

#### 17. 石垣 景子



18. 成田 綾

19. 井田 博幸

(1) Sato Y, Kobayashi H, Higuchi T, Shimada Y, Ida H, Ohashi T. Metabolomic Profiling of Pompe Disease-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals That Oxidative Stress Is Associated with Cardiac and Skeletal Muscle Pathology. *Stem Cells Transl Med.* 2017 Jan;6(1):31-39.

(2) Sato Y, Ida H, Ohashi T. Anti-BlyS antibody reduces the immune reaction against enzyme and enhances the efficacy of enzyme replacement therapy in Fabry disease model mice. *Clin Immunol.* 2017 May;178:56-63.

(3) Hoshina H, Shimada Y, Higuchi T, Kobayashi H, Ida H, Ohashi T. Chaperone effect to sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis. *Mol Genet Metab* 2017

(4) Charrow J, Fraga C, Gu X, Ida H, et al. Once-versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase3, randomized, double-blind EDGE trial. *Mol Genet and Metab.* 2018 Mar;123(3) : 347-356

(5) 柿崎 暁, 堀口昇男, 井田博幸: CYP2D6 遺伝子多型検査を経て酵素補充療法から基質合成抑制療法へ変更したゴーシェ病 型の1例. *肝臓.* 59 : 243-251, 2018

(6) 井田博幸: 小児の治療指針 Gaucher 病. *小児科診療 増刊号* : 546-548, 2018

(7) 井田博幸: Gaucher 病に対する基質合成抑制療法. *小児内科.* Vol.50 . No.10 . 2018-10

(8) Kobayashi M, Ohashi T, Kaneshiro E, Higuchi T, Ida H. Mutation spectrum of  $\alpha$ -galactosidase A gene in Japanese patients with Fabry disease. *J Hum Genet.* 2019 Jul ; 64(7) : 695-699

(9) [Nojiri A](#), [Anan I](#), [Morimoto S](#), [Kawai M](#), [Sakuma T](#), [Kobayashi M](#), [Kobayashi H](#), [Ida H](#), Ohashi T, [Eto Y](#), [Shibata T](#), [Yoshimura M](#), [Hongo K](#). Clinical findings of gadolinium-enhanced cardiac magnetic resonance in Fabry patients. *J Cardiol.* 2020 Jan ; 75(1) : 27-33

(10) Hiroyuki Ida: Gaucher Disease ,Human Pathobiochemistry eds. Ohashi T et al ,Springer ,2019:p57-66

(11) 井田博幸: 酵素補充療法の有効性と限界, 日本臨床, 日本臨床社, 2019 : 77 ; 1326-1331

20. 大橋 十也

論文投稿準備中。

21. 小林 正久

1) Kono Y, Wakabayashi T, **Kobayashi M**, Ohashi T, Eto Y, Ida H, Iguchi Y. Characteristics of cerebral microbleeds in patients with Fabry disease. *J Stroke Cerebrovasc Dis.* 2016; 25: 1320-1325

2) Higuchi T, **Kobayashi M**, Ogata J, Kaneshiro E, Shimada Y, Kobayashi H, Eto Y, Maeda S, Ohtake A, Ida H, Ohashi T. Identification of cryptic novel  $\alpha$ -Galactosidase A gene mutations: abnormal mRNA splicing and large deletions. *J Inher Metab Dis Rep.* 2016; 30: 53-72

3) **Kobayashi M**, Ohashi T, Kaneshiro E, Higuchi T, Ida H. Mutation spectrum of  $\alpha$ -galactosidase A gene in Japanese patients with Fabry disease. *J Hum Genet.* 2019; 64: 695-699

4) Hongo K, Ito K, Date T, Anan I, Inoue Y, Morimoto S, Ogawa K, Kawai M, Kobayashi H, **Kobayashi M**, Ida H, Ohashi T, Taniguchi I, Yoshimura M, Eto Y. The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients. *Mol Genet Metab.* 2018; 142: 143-151

5) Nojiri A, Anan I, Morimoto S, Kawai M, Sakuma T, Kobayashi M, Kobayashi H, Ida H, Ohashi T, Eto Y, Shibata T, Yoshimura M, Hongo K. Clinical findings of gadolinium-enhanced cardiac magnetic resonance in Fabry patients. *J Cardiol.* 2020; 75: 27-33

22. 福田 冬季子

1. 平野 恵子, 遠藤 彰, 白井 眞美, 福田 冬季子, 松林 朋子酵素補充療法中に腸間膜リンパ節の石灰化と難聴を呈した1型Gaucher病、日本小児科学会雑誌 123, 1673-1680, 2019.

2. 福田 冬季子 小児疾患の診断治療基準 糖原病 小児内科50 (増刊); 172-173, 2018.

3. 福田 冬季子 小児関連学会(分野)のガイドラインへの取り組み 神経領域(日本小児神経学会) 小児内科50(5), 808-811, 2018.

4. 福田 冬季子 小児の治療指針 ライソゾーム病 Pompe病(糖原病II型) 小児科診療81(増刊)557-558, 2018
5. 福田 冬季子 ポンペ病の新しい知見 医学のあゆみ264(9) 857-861,2018
6. Iijima H, Iwano R, Tanaka Y, Muroya K, Fukuda T, Sugie H, Kurosawa K, Adachi M. Analysis of GBE1 mutations via protein expression studies in glycogen storage disease type IV: A report on a non-progressive form with a literature review. *Mol Genet Metab Rep.* 13;17: 31-37, 2018

23. 中村 公俊

1. Watanabe S, Kido J, Ogata M, Nakamura K, Mizukami T Hyperglycemic hyperosmolar state in an adolescent with type 1 diabetes mellitus. *Endocrinol Diabetes Metab Case Rep.* 2019; 2019: 18-0131. doi: 10.1530/EDM-18-0131
2. Momosaki K, Kido J, Yoshida S, Sugawara K, Miyamoto T, Inoue T, Okumiya T, Matsumoto S, Endo F, Hirose S, and Nakamura D Newborn screening for Pompe disease in Japan: report and literature review of mutations in the GAA gene in Japanese and Asian patients. *J Hum Genet.* 2019 Aug;64(8):741-755. doi: 10.1038/s10038-019-0603-7.
3. Matsumoto S, Kido J, Sawada T, Endo F, Nakamura K Rhabdomyolysis in organic acidemia patients manifesting with metabolic decompensation. *Hemodial Int.* 2019 Sep 2. doi: 10.1111/hdi.12778.
4. Mehta A, Kuter DJ, Salek SS, Belmatoug N, Bembi B, Bright J, Vom Dahl S, Deodato F, Di Rocco M, Göker-Alpan O, Hughes DA, Lukina EA, Machaczka M, Mengel E, Nagral A, Nakamura K, Narita A, Oliveri B, Pastores G, Pérez-López J, Ramaswami U, Schwartz IV, Szer J, Weinreb NJ, Zimran A *Intern Med J.* 2019 May;49(5):578-591. doi: 10.1111/imj.14156. Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative.
5. Matsumoto S, Häberle J, Kido J, Mitsubuchi H, Endo F, Nakamura K. Urea cycle disorders-update. *J Hum Genet.* 2019 Sep;64(9):833-847. doi: 10.1038/s10038-019-0614-4. Epub 2019 May 20.
6. Suzuki Y, Kido J, Matsumoto S, Shimizu K, Nakamura K Associations among amino acid, lipid, and glucose metabolic profiles in childhood obesity. *BMC Pediatr.* 2019 Aug 6;19(1):273. doi: 10.1186/s12887-019-1647-8.
7. Sawada T, Kido J, Yoshida S, Sugawara K, Momosaki K, Inoue T, Tajima G, Sawada H, Matsumoto S, Endo F, Hirose S, Nakamura K. Newborn screening for Fabry disease in the western region of Japan. *Mol Genet Metab Rep.* 2020 Jan 11;22:100562. doi: 10.1016/j.ymgmr. 2019.100562. eCollection 2020 Mar.
8. Mehta A, Belmatoug N, Bembi B, Deegan P, Elstein D, Göker-Alpan O, Lukina E, Mengel E, Nakamura K, Pastores GM, Pérez-López J, Schwartz I, Serratrice C, Szer J, Zimran A, Rocco MD, Panahloo Z, Kuterr DJ, Hughes D Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. *Mol Genet Metabol* 122, 122-129 (2018)
9. Chong PF, Nakamura K and Kira R Mulberries in the urine: a tell-tale sign of Fabry disease. *Journal of Inherited Metabolic Disease* (in press) doi: 10.1007/s10545-018-0155-6
10. Anan K, Hino S, Shimizu N, Sakamoto A, Nagaoka K, Takase R, Kohrogi K, Araki H, Hino Y, Usuki S, Oki S, Tanaka H, Nakamura K, Endo F, Nakao M LSD1 mediates metabolic reprogramming by glucocorticoids during myogenic differentiation. *Nucleic Acids Research*, gky234, <https://doi.org/10.1093/nar/gky234>, 29 March 2018
11. Kido J, Matsumoto S, Mitsubuchi H, Sakamoto R, Nakamura K Recovery of severe acute liver failure without transplantation in patients with Wilson disease. *Pediatric Transplantation* (in press)
12. Momosaki K, Kido J, Matsumoto S, Yoshida S, Takei A, Miyabayashi T, Sugawara K, Endo F, Nakamura K High-risk screening for Gaucher disease in patients with neurological symptoms. *J Hum Genet.* 63, 717-721 (2018) doi: 10.1038/s10038-018-0438-7. Epub 2018 Mar 30.

13. Kido J, Inoue H, Suzuki Y, Tanaka M, Mitsubuchi H, Nakamura K, Endo F, Matsumoto S A significant difference in the blood carnitine values obtained by the enzymatic cycling and tandem mass spectrometry methods. *Clinical Laboratory* 64,211-215(2018)
14. Tanaka K, Nakamura K, Matsumoto S, Kido J, Mitsubuchi H, Ohura T, Endo F Citrulline administration for urea cycle disorders in Japan. *Pediatrics International* 59, 422-426 (2017). doi: 10.1111/ped.13163
- 15 . Kido J, Matsumoto S, Sakamoto R, Mitsubuchi H, Endo F and Nakamura K\* Pulmonary artery hypertension in methylmalonic academia. *Hemodialysis International* 21:E25-E29 (2017) doi: 10.1111/hdi.12506
16. Chinen Y, Nakamura S, Yoshida T, Maruyama H, Nakamura K A new mutation in newborn screening for Fabry disease evaluated by plasma globotriaosylsphingosine levels. *Human Genome Variation* 4: 17002. (2017) doi: 10.1038/hgv.2017.2
17. Sekijima Y\*, Nagamatsu K, Nakamura K, Nakamura K, Hattori K, Ota M, Shimizu Y, Endo F, and Ikeda S Prevalence of Fabry Disease and GLA c.196G>C Variant in Japanese Stroke Patients. *J Hum Genet* 62:665-670 (2017) doi: 10.1038/jhg.2017.31
18. Kido J, Kawasaki T, Mitsubuchi H, Kamohara H, Ohba T, Matsumoto S, Endo F, Nakamura K\* Hyperammonemia crisis following parturition in a female patient with ornithine transcarbamylase deficiency. *World J Hepatol.* 9:343-348 (2017) doi: 10.4254/wjgh.v9.i6.343
19. Kronn D, Day-Salvatore D, Hwu WL, Jones S, Nakamura K, Okuyama T, Scott C, Swoboda K, Kishnani P\* Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum *Pediatrics* 140:supple 1 (2017) doi: 10.1542/peds.2016-0280E
20. Sakamoto R, Matsumoto S, Shimazu T, Yoshida S, Kuraoka S, Mitsubuchi H and Nakamura K A case of treated Gaucher disease with progressive neurological damage. *Med Sci Case Rep* 4:37-40 (2017) doi: 10.12659/MSCR.904439
21. Yoshida T, Kido J, Mitsubuchi H, Matsumoto S, Endo F and Nakamura K\* Clinical manifestations in two patients with pyruvate dehydrogenase deficiency and long-term survival. *Hum Genome Var.* 4, 17020 (2017) Published online 2017 Jun 1. doi: doi: 10.1038/hgv.2017.20
22. Kido J, Matsumoto S, Sakamoto R, Mitsubuchi H, Endo F and Nakamura K Liver transplantation may prevent neurodevelopmental deterioration in high risk patients with urea cycle disorders. *Pediatr Transplant.* 21 (2017) doi: 10.1111/petr.12987. Epub 2017 Jun 12.
23. Nakamura K, Ito M, Shigematsu Y and Endo F Tyrosinemia Type I in Japan: A Report of Five Cases in Hereditary Tyrosinemia RM Tanguay (Ed) Springer 133-138 (2017)
24. Mori H, Momosaki K, Kido J, Tamura H, Tanaka K, Matsumoto S, Nakamura K, Mitsubuchi H, Endo F, Iwai M Amelioration of Brain Damage by Glycine in Neonatal Rat Brain Following Hypoxia-Ischemia. *Pediatr Int.* 59:321-327 (2017) doi: 10.1111/ped.13164
25. Kido, J; Yoshida, T; Mitsubuchi, H; Matsumoto, S; Nakamura, K Impact of the 2016 Kumamoto Earthquake on a female patient with OTCD. *Pediatr Int.* 2017 Nov;59(11):1213-1215. doi: 10.1111/ped.13419.
- 26 . Hiramatsu M and Nakamura K Elosulfase alfa enzyme replacement therapy attenuates disease progression in a non-ambulatory Japanese patient with Morquio A syndrome. *Molecular Genetics and Metabolism Report* 13, 76-79 (2017) e-publication doi: 10.1016/j.ymgmr.2017.09.001

#### 24. 浜崎 考史

- Narita I, Ohashi T, Sakai N, Hamazaki T, et.al. Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study. *CLINICAL AND EXPERIMENTAL NEPHROLOGY*24 巻 2 号 157-166 2020 年 2 月 ( 査読有り , 招待無し )
- Okuyama T, Seo Joo-Hyun, Kosuga M, Shintaku H, Hamazaki T. Successful prevention and stabilization of cognitive decline in Japanese patients with neuronopathic mucopolysaccharidosis type

II treated by intracerebroventricular enzyme replacement therapy: Results of the Phase clinical trial for two years. MOLECULAR GENETICS AND METABOLISM 129 巻 2 号 S120 2020 年 2 月( 査読有り , 招待無し)

- Maeda M, Seto T, Kadono C, Morimoto H, Kida S, Suga M, Nakamura M, Kataoka Y, Hamazaki T, Shintaku H. Autophagy in the Central Nervous System and Effects of Chloroquine in Mucopolysaccharidosis Type II Mice. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 20 巻 23 号 2019 年 12 月 ( 査読有り , 招待無し)
- 濱崎考史.ライソゾーム病-最新情報と将来展望-治療の最新情報 クリニカルクエスチョン(CQ)低分子治療薬 シャペロン治療の治療対象患者と有効性. 日本臨床 77 巻 8 号 1338-1343 2019 年 8 月
- Feldt-Rasmussen Ulla, Hughes Derralynn, Sunder-Plassmann Gere, Shankar Suma, Olivotto Iacopo, Ortiz Damara, Lachmann Robin H., Ohashi Toya, Hamazaki Takashi, Skuban Nina, Yu Julie, Barth Jay A., Nicholls Kathleen Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 30-month results from the randomized phase 3 ATTRACT study. MOLECULAR GENETICS AND METABOLISM 126 巻 2 号 S53 2019 年 2 月 ( 査読有り , 招待無し)
- Kasuga Saki, Kabata Daijiro, Sakaguchi Tomoko, Kudoh Satoshi, Nishigaki Satsuki, Higa Yusuke, Fujikawa Shiori, Fujitani Hiroko, Shintani Ayumi, Hamazaki Takashi, Shintaku Haruo Usefulness of serum biopterin as a predictive biomarker for childhood asthma control: A prospective cohort study ALLERGOLOGY INTERNATIONAL 68 巻 1 号 96-100 2019 年 1 月 ( 査読有り , 招待無し)
- Hoshina T, Nozaki S, Hamazaki T, Kudo S, Nakatani Y, Kodama H, Shintaku H, Watanabe Y Disulfiram enhanced delivery of orally administered copper into the central nervous system in Menkes disease mouse model. Journal of inherited metabolic disease 2018 年 8 月 21 日 ( 査読有り , 招待無し)
- 尾崎 正典, 下野 太郎, 濱崎 考史, 立川 裕之, 三木 幸雄. 小脳萎縮を伴った GM1 ガングリオシドーシス type 2 の 1 例臨床放射線 63 巻 4 号 455-459 2018 年 4 月 ( 査読有り , 招待無し)
- Nicholls K, Shankar SP, Sunder-Plassmann G, Koehler D, Nedd K, Vockley G, Hamazaki T et. al. Oral Pharmacological Chaperone Migalastat Compared With Enzyme Replacement Therapy in Fabry Disease: 18-Month Results from the Randomized Phase 3 ATTRACT Study. Journal of Medical Genetics 2017 J Med Genet. ;54(4):288-296. ( 査読有)
- Hamazaki T, El Roubi N, Fredette NC, Santostefano KE, Terada N. Induced Pluripotent Stem Cell Research in the Era of Precision Medicine. Stem Cells 2017 Mar;35(3):545-550 ( 査読有)
- Kubaski F, Yabe H, Suzuki Y, Seto T, Hamazaki T et al. Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II. Biol Blood Marrow Transplant. 2017 23(10):1795-1803. ( 査読有 )

## 25. 秋山 けい子

- 1) Hossain MA, Wu C, Yanagisawa H, Miyajima T, Akiyama K, Eto Y. Future clinical and biochemical predictions of Fabry disease in females by methylation studies of the *GLA* gene. Mol Gent Metab Rep. 2019 Jul;20:100497.

## 26. 矢部 普正

1. Yabe H, Tabuchi K, Uchida N, Takahashi S, Onishi Y, Aotsuka N, Sugio Y, Ikegame K, Ichinohe T, Takanashi M, Kato K, Atsuta Y, Kanda Y. Could the minimum number of hematopoietic stem cells to obtain engraftment exist in unrelated, single cord blood transplantation? Br J Haematol. 2020 Feb 28. doi: 10.1111/bjh.16465. [Epub ahead of print] No abstract available. PMID: 32108331
2. Yamazaki N, Kosuga M, Kida K, Takei G, Fukuhara Y, Matsumoto H, Senda M, Honda A, Ishiguro A, Koike T, Yabe H, Okuyama T. Early enzyme replacement therapy enables a successful hematopoietic stem cell transplantation in mucopolysaccharidosis type IH: Divergent clinical outcomes in two Japanese siblings. Brain

and development 2019 (in press)

3. Donovan FX, Solanki A, Mori M, Chavan N, George M, Kumar C S, Okuno Y, Muramatsu H, Yoshida K, Shimamoto A, Takaori-Kondo A, Yabe H, Ogawa S, Kojima S, Yabe M, Ramanagoudr-Bhojappa R, Smogorzewska A, Mohan S, Rajendran A, Auerbach AD, Takata M, Chandrasekharappa SC, Vundinti BR. A founder variant in the South Asian population leads to a high prevalence of FANCL Fanconi anemia cases in India. *Hum Mutat*. 2019 Sep 12. doi: 10.1002/humu.23914. [Epub ahead of print]
4. Hyakuna N, Hashii Y, Ishida H, Umeda K, Takahashi Y, Nagasawa M, Yabe H, Nakazawa Y, Koh K, Goto H, Fujisaki H, Matsumoto K, Kakuda H, Yano M, Tawa A, Tomizawa D, Taga T, Adachi S, Kato K. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial. *Pediatr Blood Cancer*. 2019 Oct;66(10):e27875. doi: 10.1002/pbc.27875. Epub 2019 Jul 16.
5. Iguchi A, Cho Y, Yabe H, Kato S, Kato K, Hara J, Koh K, Takita J, Ishihara T, Inoue M, Imai K, Nakayama H, Hashii Y, Morimoto A, Atsuta Y, Morio T; Hereditary disorder Working Group of the Japan Society for Hematopoietic Cell Transplantation. Long-term outcome and chimerism in patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation: a retrospective nationwide survey. *Int J Hematol*. 2019 Jun 11. doi: 10.1007/s12185-019-02686-y. [Epub ahead of print] PMID: 31187438
6. Matsuda M, Ono R, Iyoda T, Endo T, Iwasaki M, Tomizawa-Murasawa M, Saito Y, Kaneko A, Shimizu K, Yamada D, Ogonuki N, Watanabe T, Nakayama M, Koseki Y, Kezuka-Shiotani F, Hasegawa T, Yabe H, Kato S, Ogura A, Shultz LD, Ohara O, Taniguchi M, Koseki H, Fujii SI, Ishikawa F. Human NK cell development in hIL-7 and hIL-15 knockin NOD/SCID/IL2rgKO mice. *Life Sci Alliance*. 2019 Apr 1;2(2). pii: e201800195. doi: 10.26508/lsa.201800195. Print 2019 Apr. PMID: 30936185
7. Mori M, Hira A, Yoshida K, Muramatsu H, Okuno Y, Shiraishi Y, Anmae M, Yasuda J, Tadaka S, Kinoshita K, Osumi T, Noguchi Y, Adachi S, Kobayashi R, Kawabata H, Imai K, Morio T, Tamura K, Takaori-Kondo A, Yamamoto M, Miyano S, Kojima S, Ito E, Ogawa S, Matsuo K, Yabe H, Yabe M, Takata M. Pathogenic mutations identified by a multimodality approach in 117 Japanese Fanconi anemia patients. *Haematologica*. 2019; 104(10): 1962-1973.
8. Taylor M, Khan S, Stapleton M, Wang J, Chen J, Wynn R, Yabe H, Chinen Y, Boelens JJ, Mason RW, Kubaski F, Horovitz DDG, Barth AL, Serafini M, Bernardo ME, Kobayashi H, Orri KE, Suzuki Y, Orri T, Tomatsu S. Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future. *Biol Blood Marrow Transplant*. 2019 Feb 14. pii: S1083-8791(19)30137-5. doi: 10.1016/j.bbmt.2019.02.012. [Epub ahead of print] Review.
9. Ono R, Watanabe T, Kawakami E, Iwasaki M, Tomizawa-Murasawa M, Matsuda M, Najima Y, Takagi S, Fujiki S, Sato R, Mochizuki Y, Yoshida H, Sato K, Yabe H, Kato S, Saito Y, Taniguchi S, Shultz LD, Ohara O, Amagai M, Koseki H, Ishikawa F. Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model. *EBioMedicine*. 2019 Mar;41:584-596. doi: 10.1016/j.ebiom.2019.02.001. Epub 2019 Feb 13.
10. Yamazaki N, Kosuga M, Kida K, Takei G, Fukuhara Y, Matsumoto H, Senda M, Honda A, Ishiguro A, Koike T, Yabe H, Okuyama T. Early enzyme replacement therapy enables a successful hematopoietic stem cell transplantation in mucopolysaccharidosis type IH: Divergent clinical outcomes in two Japanese siblings. *Brain Dev*. 2019 Feb 9. pii: S0387-7604(18)30541-2. doi: 10.1016/j.braindev.2019.01.008. [Epub ahead of print]
11. Miyamura K, Yamashita T, Atsuta Y, Ichinohe T, Kato K, Uchida N, Fukuda T, Ohashi K, Ogawa H, Eto T, Inoue M, Takahashi S, Mori T, Kanamori H, Yabe H, Hama A, Okamoto S, Inamoto Y. High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation. *Blood Adv*. 2019 Feb 12;3(3):397-405. doi:
12. Okamoto Y, Kudo K, Tabuchi K, Tomizawa D, Taga T, Goto H, Yabe H, Nakazawa Y, Koh K, Ikegame K, Yoshida N, Uchida N, Watanabe K, Koga Y, Inoue M, Kato K, Atsuta Y, Ishida H. Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. *Bone Marrow Transplant*. 2019 Feb 4. doi: 10.1038/s41409-019-0461-0. [Epub ahead of print]
13. Kawashima N, Iida M, Suzuki R, Fukuda T, Atsuta Y, Hashii Y, Inoue M, Kobayashi M, Yabe H, Okada K, Adachi S, Yuza Y, Kawa K, Kato K. Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan. *Int J Hematol*. 2019 Jan 29. doi: 10.1007/s12185-019-02601-5. [Epub ahead of print]
14. Umeda K, Yabe H, Kato K, Imai K, Kobayashi M, Takahashi Y, Yoshida N, Sato M, Sasahara Y, Kato K, Adachi S, Koga Y, Okada K, Inoue M, Hashii Y, Atsuta Y, Morio T; Inherited Disease Working Group of the Japan Society for Hematopoietic Cell Transplantation. Impact of low-dose irradiation and in vivo T-cell depletion on hematopoietic stem cell transplantation for non-malignant diseases using fludarabine-based reduced-intensity conditioning. *Bone Marrow Transplant*. 2018 Dec 7. doi: 10.1038/s41409-018-0418-8. [Epub ahead of print]
15. Yabe M, Koike T, Ohtsubo K, Imai E, Morimoto T, Takakura H, Koh K, Yoshida K, Ogawa S, Ito E, Okuno Y, Muramatsu H, Kojima S, Matsuo K, Mori M, Hira A, Takata M, Yabe H. Associations of complementation

- group, ALDH2 genotype, and clonal abnormalities with hematological outcome in Japanese patients with Fanconi anemia. *Ann Hematol.* 2018 Oct 27. doi: 10.1007/s00277-018-3517-0. [Epub ahead of print]
16. Yakushijin K, Ikezoe T, Ohwada C, Kudo K, Okamura H, Goto H, Yabe H, Yasumoto A, Kuwabara H, Fujii S, Kagawa K, Ogata M, Onishi Y, Kohno A, Watamoto K, Uoshima N, Nakamura D, Ota S, Ueda Y, Oyake T, Koike K, Mizuno I, Iida H, Katayama Y, Ago H, Kato K, Okamura A, Kikuta A, Fukuda T. Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2018 Aug 20. doi: 10.1038/s41409-018-0304-4. [Epub ahead of print]
  17. Inamoto Y, Matsuda T, Tabuchi K, Kurosawa S, Nakasone H, Nishimori H, Yamasaki S, Doki N, Iwato K, Mori T, Takahashi S, Yabe H, Kohno A, Nakamae H, Sakura T, Hashimoto H, Sugita J, Ago H, Fukuda T, Ichinohe T, Atsuta Y, Yamashita T; Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group. Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation. *Blood Adv.* 2018 Aug 14;2(15):1901-1913. doi: 10.1182/bloodadvances.2018020966.
  18. Nakasone H, Tabuchi K, Uchida N, Ohno Y, Matsuhashi Y, Takahashi S, Onishi Y, Onizuka M, Kobayashi H, Fukuda T, Ichinohe T, Takanashi M, Kato K, Atsuta Y, Yabe H, Kanda Y. Which is more important for the selection of cord blood units for haematopoietic cell transplantation: the number of CD34-positive cells or total nucleated cells? *Br J Haematol.* 2018 May 29. doi: 10.1111/bjh.15418. [Epub ahead of print]
  19. Takahashi H, Kajiwara R, Kato M, Hasegawa D, Tomizawa D, Noguchi Y, Koike K, Toyama D, Yabe H, Kajiwara M, Fujimura J, Sotomatsu M, Ota S, Maeda M, Goto H, Kato Y, Mori T, Inukai T, Shimada H, Fukushima K, Ogawa C, Makimoto A, Fukushima T, Ohki K, Koh K, Kiyokawa N, Manabe A, Ohara A. Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16. *Int J Hematol.* 2018 Jul;108(1):98-108. doi: 10.1007/s12185-018-2440-4. Epub 2018 Mar 27.
  20. Oshima K, Saiki N, Tanaka M, Imamura H, Niwa A, Tanimura A, Nagahashi A, Hirayama A, Okita K, Hotta A, Kitayama S, Osawa M, Kaneko S, Watanabe A, Asaka I, Fujibuchi W, Imai K, Yabe H, Kamachi Y, Hara J, Kojima S, Tomita M, Soga T, Noma T, Nonoyama S, Nakahata T, Saito MK. Human AK2 links intracellular bioenergetic redistribution to the fate of hematopoietic progenitors. *Biochem Biophys Res Commun.* 2018 Mar 4;497(2):719-725. doi: 10.1016/j.bbrc.2018.02.139. Epub 2018 Feb 17.
  21. Horikoshi Y, Umeda K, Imai K, Yabe H, Sasahara Y, Watanabe K, Ozawa Y, Hashii Y, Kurosawa H, Nonoyama S, Morio T. Allogeneic Hematopoietic Stem Cell Transplantation for Leukocyte Adhesion Deficiency. *J Pediatr Hematol Oncol.* 2018 Jan 10. doi: 10.1097/MPH.0000000000001028. [Epub ahead of print]
  22. Morishima Y, Azuma F, Kashiwase K, Matsumoto K, Orihara T, Yabe H, Kato S, Kato K, Kai S, Mori T, Nakajima K, Morishima S, Satake M, Takanashi M, Yabe T; Japanese Cord Blood Transplantation Histocompatibility Research Group. Risk of HLA Homozygous Cord Blood Transplantation: Implications for Induced Pluripotent Stem Cell Banking and Transplantation. *Stem Cells Transl Med.* 2018 Feb;7(2):173-179. doi: 10.1002/sctm.17-0169. Epub 2017 Dec 23.
  23. Stapleton M, Kubaski F, Mason RW, Yabe H, Suzuki Y, Orii KE, Orii T, Tomatsu S. Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome). *Expert Opin Orphan Drugs.* 2017;5(4):295-307. doi: 10.1080/21678707.2017.1296761. Epub 2017 Mar 8. PMID: 29158997
  24. Onishi Y, Mori T, Kako S, Koh H, Uchida N, Kondo T, Kobayashi T, Yabe H, Miyamoto T, Kato K, Suzuki R, Nakao S, Yamazaki H; Adult Aplastic Anemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. *Biol Blood Marrow Transplant.* 2017 Aug 24. pii: S1083-8791(17)30655-9. doi: 10.1016/j.bbmt.2017.08.020. [Epub ahead of print]
  25. Kubaski F, Yabe H, Suzuki Y, Seto T, Hamazaki T, Mason RW, Xie L, Onsten TGH, Leistner-Segal S, Giugliani R, D'ŕing VC, Ngoc CTB, Yamaguchi S, Montañŕo AM, Orii KE, Fukao T, Shintaku H, Orii T, Tomatsu S. Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II. *Biol Blood Marrow Transplant.* 2017 Oct;23(10):1795-1803. doi: 10.1016/j.bbmt.2017.06.020. Epub 2017 Jul 1.
  26. Sekinaka Y, Mitsuiki N, Imai K, Yabe M, Yabe H, Mitsui-Sekinaka K, Honma K, Takagi M, Arai A, Yoshida K, Okuno Y, Shiraiishi Y, Chiba K, Tanaka H, Miyano S, Muramatsu H, Kojima S, Hira A, Takata M, Ohara O, Ogawa S, Morio T, Nonoyama S. Common Variable Immunodeficiency Caused by FANC Mutations. *J Clin Immunol.* 2017 Jul;37(5):434-444. doi: 10.1007/s10875-017-0396-4. Epub 2017 May 11.
  27. Hoenig M, Lagresle-Peyrou C, Pannicke U, Notarangelo LD, Porta F, Gennery AR, Slatte M, Cowan MJ, Stepensky P, Al-Mousa H, Al-Zahrani D, Pai SY, Al Herz W, Gaspar HB, Veys P, Oshima K, Imai K, Yabe H,

Noroski LM, Wulffraat NM, Sykora KW, Soler-Palacin P, Muramatsu H, Al Hilali M, Moshous D, Debatin KM, Schuetz C, Jacobsen EM, Schulz AS, Schwarz K, Fischer A, Friedrich W, Cavazzana M. Reticular dysgenesis: international survey on clinical presentation, transplantation and outcome. *Blood*. 2017 Mar 22. pii: blood-2016-11-745638. doi: 10.1182/blood-2016-11-745638. [Epub ahead of print]

著書

1. 指定難病ペディア 2019 ファンconi貧血 日本医師会 2019 190-191 (共著)
2. Mucopolysaccharidoses update. Hematopoietic Stem Cell Transplantation in Mucopolysaccharidoses: The Effects and Limitations (Chapter 24) *Tomatsu S, Orii T ed* Nova Science New York 2018.

難病研究 up-to-date 造血幹細胞移植 メディカルドゥ 2017 123-129 (共著)